Eli Lilly's Revenue Rose 39% As Volume Added 53 Points And Price Took Away 15

Investment Thesis

Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39%. The company's own growth decomposition is what makes the quarter instructive: volume added 53 percentage points and price subtracted 15. Reported EPS was $7.22 and non-GAAP EPS $7.48, after acquired in-process research and development (IPR&D) charges of about $4.2 billion, or about $4.57 per share. Full-year revenue guidance was raised to $91 billion to $92 billion from $85 billion to $87 billion. Source caution: I could not open Lilly's own release. These figures come from two secondary summaries (ChemXplore and 247WallSt), so treat them as unverified until checked against Lilly's filing.

• Revenue. $24.4B, +39%; volume +53%, price -15%; US $15.1B (+34%); international $9.3B (+47%).
• Earnings. Reported EPS $7.22; non-GAAP EPS $7.48; IPR&D $4.18B to $4.2B (about $4.57 per share).
• Other items. About $900M of other benefits, including a $410M Jardiance milestone. A China reimbursement-list price effect is cited.
• Guidance. 2026 revenue $91B to $92B (previously $85B to $87B).
• Not in my sources. Product-level splits and 2026 EPS guidance.
• This article contains no rating, price target or investment advice. Derived figures are marked (d).

Bottom line. Lilly's growth is a volume story with falling prices, which is the pattern of a product category expanding into more patients while each unit earns less. For investors the useful measure is not the headline growth but how much of the volume comes at a lower price, how much profit survives the research charges, and whether guidance rises with the quarter's strength. Guidance rose by about $5.5 billion at the midpoint (d).

Sources (secondary): ChemXplore; 247WallSt.

Q3 2026 At A Glance

Sources (secondary): ChemXplore; 247WallSt.

What The Market Believes vs. What The Data Actually Shows

Forensic #1: Price Versus Volume

Lilly Q3 2026 Revenue Growth: Volume, Price And Total (Self-Made, d)

The components are additive contributions measured against last year's revenue, so +53 and -15 give +38, and the remaining point to +39 is other items (d), which may include currency. They are not compounding rates. Prior-year revenue was about $17.6 billion (d: $24.4B / 1.39). A 15-point price contribution therefore removed about $2.6 billion (d: 15% x $17.6B) of revenue, while volume added about $9.3 billion (d: 53% x $17.6B).

Why it matters. When prices fall and volumes expand, the key question is elasticity: does each point of price cut bring more than a point of volume? Here 15 points of price came alongside 53 points of volume, a ratio of about 3.5 to 1 (d), which is favourable. It does not prove that the price cuts caused the volume, since the extract says the China reimbursement-list change is one source of the price effect and other drivers may have raised volume independently.

Sources (secondary): ChemXplore; 247WallSt. Dollar effects are my arithmetic (d).

Forensic #2: Geography

Lilly Q3 2026 Revenue Growth By Region (Self-Made, Secondary Data)

International revenue rose by about $3.0 billion (d: $9.3B less $6.3B) against about $3.8 billion (d) for the US, so the US still contributed more dollars. Of the $6.8 billion total increase (d), 56% came from the US (d) and 44% from international (d). The cited China reimbursement-list price effect sits in the international line, but the extract does not give its size.

Why it matters. International growth at 47% is faster than the US, but it is the more exposed to price resets of the kind named for China. The price component (-15 points) is not split by region in my sources.

Sources (secondary): ChemXplore; 247WallSt. Derived figures marked (d).

Forensic #3: Earnings Quality And IPR&D

Lilly Q3 2026 EPS With And Without IPR&D (Self-Made, d)

Acquired IPR&D is a cost of buying research assets that are not yet approved. Lilly's non-GAAP EPS of $7.48 is only $0.26 above GAAP, so the non-GAAP measure appears to include the IPR&D charge and exclude only smaller items (that is my reading of the numbers, not a statement I can check against the release). Adding the $4.57 back gives about $11.79 and $12.05 (d), but those figures assume the per-share amount applies to both measures and ignore any tax effect. The implied share count of about 915 million (d: $4.18B / $4.57) is only a cross-check. The roughly $900 million of other benefits, about $0.98 per share before tax (d), partly offsets the charge.

Why it matters. Large IPR&D charges are a recurring part of a pharmaceutical company's investment in its pipeline. They do not distort the cash cost of the deals, but they do make quarter-to-quarter EPS volatile. A stable view needs several quarters.

Sources (secondary): ChemXplore; 247WallSt. Derived figures marked (d).

Forensic #4: Guidance

The range narrowed and rose: the low end moved up by $6 billion and the high end by $5 billion (d). The raise is about 6.4% of the old midpoint (d). I have no year-to-date revenue in my sources, so I cannot work out the revenue implied for the fourth quarter. I also have no EPS guidance.

Why it matters. A raise of about 6% (d) at the midpoint says management sees more revenue than it did, and the next question is whether volume growth stays ahead of the price decline.

Sources (secondary): ChemXplore; 247WallSt.

Valuation Snapshot

I have no Lilly share price in my sources, so I do not calculate multiples. The earnings base is quarterly EPS of $7.22 (GAAP) or $7.48 (non-GAAP), with about $4.57 per share of IPR&D in the quarter.

What has to be true. For revenue to meet the raised $91 billion to $92 billion, volume growth must stay far above the price decline. Any further price resets, such as the China change, subtract directly from that.

Risks: What Would Break The Thesis

• Secondary sources. Lilly's release was not opened.
• Additive growth. Contributions are percentage points and rounding can hide detail.
• IPR&D treatment. My add-back assumes the same $4.57 applies to both EPS measures.
• Pricing. Price already subtracts 15 points and the extract names China as one driver.
• Missing data. No product splits, no EPS guidance, no price.

The reading would be wrong if Lilly's release shows a different IPR&D treatment or if the price effect is concentrated in a one-off.

What To Watch Next

• Lilly's own Q3 release and 10-Q, to check each figure here.
• The next quarter's volume and price contributions.
• IPR&D charges and business-development spending.
• Fourth-quarter revenue against the $91B to $92B range.
• International growth after the China reimbursement-list price effect.
• Any change to EPS guidance.